<p>紐約，NY / ACCESS Newswire /2025 年 10 月 27 日/ 如果您在 <strong>Baxter International, Inc.</strong> 的投資中遭受損失，並希望瞭解根據聯邦證券法的潛在賠償，請點擊以下鏈接獲取更多信息：</p>
<p>https://zlk.com/pslra-1/baxter-international-inc-lawsuit-submission-form?prid=174065&amp;wire=1&amp;utm_campaign=24</p>
<p>或通過電子郵件聯繫 Joseph E. Levi 律師，郵箱為 jlevi@levikorsinsky.com，或撥打 (212) 363-7500 與我們經驗豐富的股東倡導團隊聯繫。</p>
<p><strong>訴訟：</strong> 針對 Baxter International, Inc.提起了一項集體訴訟，旨在追回在 2022 年 2 月 23 日至 2025 年 7 月 30 日期間因涉嫌證券欺詐而受到不利影響的股東損失。</p>
<p><strong>案件詳情：</strong> 提交的投訴指控被告發表虛假陳述和/或隱瞞了以下事實：(a) Baxter 最近推出的產品 Novum LVP 存在系統性缺陷，導致廣泛的故障，包括輸液不足、輸液過量和完全不輸液，給患者帶來了嚴重傷害或死亡的風險；(b) Baxter 已被通知多起設備故障、傷害和因這些缺陷導致的死亡；(c) Baxter 通過客户警報來解決這些缺陷的嘗試是不充分的補救措施，因為設計缺陷仍然存在並繼續對患者造成嚴重傷害；(d) 因此，客户被指示將現有的 Novum LVP 停用的風險增加，Baxter 將完全暫停所有新銷售這些泵的可能性；(e) 基於上述情況，Baxter 關於 Novum LVP 的安全性、有效性、產品推出、客户反饋和銷售前景的陳述是實質性虛假和誤導的。</p>
<p><strong>接下來怎麼辦？</strong> 如果您在相關時間段內在 Baxter International, Inc.的股票中遭受損失——即使您仍持有股份——請訪問 https://zlk.com/pslra-1/baxter-international-inc-lawsuit-submission-form?prid=174065&amp;wire=1&amp;utm_campaign=24 瞭解您尋求賠償的權利。<strong>參與沒有費用或義務。</strong></p>
<p><strong>為什麼選擇 LEVI &amp; KORSINSKY：</strong> 在過去 20 年中，Levi &amp; Korsinsky LLP 已建立為全國知名的證券訴訟公司，為受害股東爭取了數億美元，並在高風險案件中贏得了良好的記錄。該公司在複雜證券訴訟方面擁有豐富的專業知識，並擁有超過 70 名員工為客户服務。連續七年，Levi &amp; Korsinsky 在 ISS 證券集體訴訟服務的前 50 報告中被評為美國頂級證券訴訟公司之一。律師廣告。以往的結果並不保證類似的結果。</p>
<p><strong>聯繫方式：</strong></p>
<p>Levi &amp; Korsinsky, LLP</p>
<p>Joseph E. Levi, Esq.</p>
<p>Ed Korsinsky, Esq.</p>
<p>33 Whitehall Street, 27th Floor</p>
<p>紐約，NY 10004</p>
<p>jlevi@levikorsinsky.com</p>
<p>電話：(212) 363-7500</p>
<p>傳真：(212) 363-7171</p>
<p>https://zlk.com/</p>
<p><strong>來源：</strong> Levi &amp; Korsinsky, LLP</p>
<p>查看 ACCESS Newswire 上的原始新聞稿</p>

<p>針對百特國際公司（Baxter International, Inc.，股票代碼：BAX）提起了一項集體訴訟，指控其在 2022 年 2 月 23 日至 2025 年 7 月 30 日期間存在證券欺詐行為。訴狀稱，百特的 Novum LVP 產品存在系統性缺陷，導致嚴重的患者風險，並且公司關於該產品安全性和有效性的聲明具有誤導性。遭受損失的股東被鼓勵聯繫 Levi & Korsinsky LLP，以尋求潛在的賠償選項</p>

<p>NEW YORK, NY / ACCESS Newswire / October 27, 2025 / If you suffered a loss on your <strong>Baxter International, Inc.</strong> investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:</p>
<div class="lb-trans"><p>紐約，NY / ACCESS Newswire /2025 年 10 月 27 日/ 如果您在 <strong>Baxter International, Inc.</strong> 的投資中遭受損失，並希望瞭解根據聯邦證券法的潛在賠償，請點擊以下鏈接獲取更多信息：</p>
</div><p>https://zlk.com/pslra-1/baxter-international-inc-lawsuit-submission-form?prid=174065&amp;wire=1&amp;utm_campaign=24</p>
<div class="lb-trans"><p>https://zlk.com/pslra-1/baxter-international-inc-lawsuit-submission-form?prid=174065&amp;wire=1&amp;utm_campaign=24</p>
</div><p>or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.</p>
<div class="lb-trans"><p>或通過電子郵件聯繫 Joseph E. Levi 律師，郵箱為 jlevi@levikorsinsky.com，或撥打 (212) 363-7500 與我們經驗豐富的股東倡導團隊聯繫。</p>
</div><p><strong>THE LAWSUIT:</strong> A class action securities lawsuit was filed against Baxter International, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 23, 2022 and July 30, 2025.</p>
<div class="lb-trans"><p><strong>訴訟：</strong> 針對 Baxter International, Inc.提起了一項集體訴訟，旨在追回在 2022 年 2 月 23 日至 2025 年 7 月 30 日期間因涉嫌證券欺詐而受到不利影響的股東損失。</p>
</div><p><strong>CASE DETAILS:</strong> The filed complaint alleges that defendants made false statements and/or concealed that: (a) Baxter's recently launched product, the Novum LVP, suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-delivery of fluids, which exposed patients to risks of serious injury or death; (b) Baxter was notified of multiple device malfunctions, injuries, and deaths from these defects; (c) Baxter's attempts to address these defects through customer alerts were inadequate remedial measures, when design flaws persisted and continued to cause serious harm to patients; (d) as a result, there was a heightened risk that customers would be instructed to take existing Novum LVPs out of service and that Baxter would completely pause all new sales of these pumps; and (e) based on the foregoing, Baxter's statements about the safety, efficacy, product rollout, customer feedback and sales prospects of the Novum LVPs were materially false and misleading.</p>
<div class="lb-trans"><p><strong>案件詳情：</strong> 提交的投訴指控被告發表虛假陳述和/或隱瞞了以下事實：(a) Baxter 最近推出的產品 Novum LVP 存在系統性缺陷，導致廣泛的故障，包括輸液不足、輸液過量和完全不輸液，給患者帶來了嚴重傷害或死亡的風險；(b) Baxter 已被通知多起設備故障、傷害和因這些缺陷導致的死亡；(c) Baxter 通過客户警報來解決這些缺陷的嘗試是不充分的補救措施，因為設計缺陷仍然存在並繼續對患者造成嚴重傷害；(d) 因此，客户被指示將現有的 Novum LVP 停用的風險增加，Baxter 將完全暫停所有新銷售這些泵的可能性；(e) 基於上述情況，Baxter 關於 Novum LVP 的安全性、有效性、產品推出、客户反饋和銷售前景的陳述是實質性虛假和誤導的。</p>
</div><p><strong>WHAT'S NEXT?</strong> If you suffered a loss in Baxter International, Inc. stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/baxter-international-inc-lawsuit-submission-form?prid=174065&amp;wire=1&amp;utm_campaign=24 to learn about your rights to seek a recovery. <strong>There is no cost or obligation to participate.</strong></p>
<div class="lb-trans"><p><strong>接下來怎麼辦？</strong> 如果您在相關時間段內在 Baxter International, Inc.的股票中遭受損失——即使您仍持有股份——請訪問 https://zlk.com/pslra-1/baxter-international-inc-lawsuit-submission-form?prid=174065&amp;wire=1&amp;utm_campaign=24 瞭解您尋求賠償的權利。<strong>參與沒有費用或義務。</strong></p>
</div><p><strong>WHY LEVI &amp; KORSINSKY:</strong> Over the past 20 years, Levi &amp; Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.</p>
<div class="lb-trans"><p><strong>為什麼選擇 LEVI &amp; KORSINSKY：</strong> 在過去 20 年中，Levi &amp; Korsinsky LLP 已建立為全國知名的證券訴訟公司，為受害股東爭取了數億美元，並在高風險案件中贏得了良好的記錄。該公司在複雜證券訴訟方面擁有豐富的專業知識，並擁有超過 70 名員工為客户服務。連續七年，Levi &amp; Korsinsky 在 ISS 證券集體訴訟服務的前 50 報告中被評為美國頂級證券訴訟公司之一。律師廣告。以往的結果並不保證類似的結果。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>聯繫方式：</strong></p>
</div><p>Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p>Levi &amp; Korsinsky, LLP</p>
</div><p>Joseph E. Levi, Esq.</p>
<div class="lb-trans"><p>Joseph E. Levi, Esq.</p>
</div><p>Ed Korsinsky, Esq.</p>
<div class="lb-trans"><p>Ed Korsinsky, Esq.</p>
</div><p>33 Whitehall Street, 27th Floor</p>
<div class="lb-trans"><p>33 Whitehall Street, 27th Floor</p>
</div><p>New York, NY 10004</p>
<div class="lb-trans"><p>紐約，NY 10004</p>
</div><p>jlevi@levikorsinsky.com</p>
<div class="lb-trans"><p>jlevi@levikorsinsky.com</p>
</div><p>Tel: (212) 363-7500</p>
<div class="lb-trans"><p>電話：(212) 363-7500</p>
</div><p>Fax: (212) 363-7171</p>
<div class="lb-trans"><p>傳真：(212) 363-7171</p>
</div><p>https://zlk.com/</p>
<div class="lb-trans"><p>https://zlk.com/</p>
</div><p><strong>SOURCE:</strong> Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p><strong>來源：</strong> Levi &amp; Korsinsky, LLP</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新聞稿</p>
</div>

追回投資損失：已對 Baxter International, Inc.（BAX）發起集體訴訟